Eli Lilly reports broad benefits for experimental obesity drug retatrutide
View original at seekingalpha.comEli Lilly reports broad benefits for experimental obesity drug retatrutide [Worried mature man measuring his waist in a living room] Ljupco/iStock via Getty Images Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) on Saturday reported positive results from two late-stage clinical trials of its experimental obesity…
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
In TRIUMPH-1, adults with obesity receiving the highest dose of retatrutide lost an average of 70.3 pounds (28.3% body weight) after 80 weeks
60% confidenceAbout one-third of highest-dose participants reached a BMI below 25, generally considered a healthy weight range
60% confidenceGLP-1 drug market sales forecast raised to $150 billion
60% confidenceAmong more severely obese participants treated for two years, average weight loss reached 85 pounds (38.56 kg)
60% confidenceIn TRANSCEND-T2D-1, retatrutide reduced A1C levels by up to 2 percentage points over 40 weeks in type 2 diabetes patients starting at an average A1C of 7.9%
60% confidenceRetatrutide reduced breathing interruptions in obstructive sleep apnea by up to 36.1 events per hour, representing roughly a 61% improvement
60% confidenceHighest-dose T2D patients lost average 36.6 pounds (16.8% body weight) and weight loss had not yet leveled off by study end
60% confidenceMore than 65% of highest-dose TRIUMPH-1 participants reduced BMI below 30, no longer meeting the medical definition of obesity
60% confidenceRetatrutide improved triglycerides, non-HDL cholesterol, blood pressure, and waist circumference across both studies
60% confidenceUp to 90% of type 2 diabetes patients receiving retatrutide achieved A1C below 7%; nearly half reached A1C below 5.7% (normal range)
60% confidenceRetatrutide reduced knee osteoarthritis pain scores by as much as 73%
60% confidenceDiscontinuation rates due to side effects ranged from approximately 2% to 11% depending on study and dose level
60% confidence